非透析依赖性CKD患者中异麦芽糖铁1000与蔗糖铁的疗效与安全性:FERWON-NEPHRO随机对照试验
FERWON-NEPHRO随机开放标签多中心试验纳入1538例非透析依赖性CKD合并缺铁性贫血患者,按2:1随机接受单次1000 mg异麦芽糖铁1000(IIM)或蔗糖铁(IS,200 mg静脉注射最多5次)。结果显示两组严重或重度超敏反应发生率无显著差异,IIM组复合心血管不良事件发生率显著低于IS组,且IIM在8周血红蛋白变化方面非劣于IS。
要点
- 单次1000 mg IIM与多次蔗糖铁相比,8周血红蛋白改善非劣效。
- IIM组严重或重度超敏反应发生率为0.3%,与IS组0%无显著差异。
- IIM组复合心血管不良事件发生率显著低于IS组(4.1%对6.9%,P=0.025)。
核心结论
- 在非透析依赖性CKD合并缺铁性贫血患者中,单次1000 mg IIM与多次蔗糖铁相比,8周血液学应答非劣效,超敏反应率低且相当,复合心血管不良事件发生率显著更低。
研究设计与样本
- 随机、开放标签、多中心试验(美国),患者按2:1随机接受单次1000 mg IIM或蔗糖铁200 mg静脉注射最多5次(2周内)。
- 共纳入1538例非透析依赖性CKD合并缺铁性贫血患者,平均eGFR 35.5 mL/min/1.73 m2。
- 共同主要终点为严重或重度超敏反应发生率及第8周血红蛋白较基线的变化。
主要发现
- 严重或重度超敏反应发生率:IIM组0.3%,IS组0%,风险差0.29%(95%CI:-0.19;0.77;P>0.05)。
- 复合心血管不良事件发生率:IIM组4.1%,IS组6.9%(P=0.025)。
- 与IS相比,IIM在最初4周内血红蛋白升高更明显(P≤0.021),第8周血红蛋白变化显示非劣效。
临床怎么用
- 对于非透析依赖性CKD合并缺铁性贫血患者,可考虑单次1000 mg IIM作为一种安全有效的静脉铁选择,且心血管不良事件风险较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia. METHODS: In this randomized, open-label and multi-centre trial conducted in the USA, patients were randomized 2:1 to a single dose of 1000 mg IIM or iron sucrose (IS) administered as 200 mg IV injections up to five times within a 2-week period. The co-primary endpoints were serious or severe hypersensitivity reactions and change in haemoglobin (Hb) from baseline to Week 8. Secondary endpoints included incidence of composite cardiovascular adverse events (AEs). RESULTS: A total of 1538 patients were enrolled (mean estimated glomerular filtration rate 35.5 mL/min/1.73 m2). The co-primary safety objective was met based on no significant difference in the incidence of serious or severe hypersensitivity reactions in the IIM and IS groups [0.3% versus 0%; risk difference: 0.29% (95% confidence interval: -0.19; 0.77; P > 0.05)]. Incidence of composite cardiovascular AEs was significantly lower in the IIM versus IS group (4.1% versus 6.9%; P = 0.025). Compared with IS, IIM led to a more pronounced increase in Hb during the first 4 weeks (P ≤ 0.021), and change in Hb to Week 8 showed non-inferiority, confirming that the co-primary efficacy objective was met. CONCLUSIONS: Compared with multiple doses of IS, a single dose of IIM induced a non-inferior 8-week haematological response, comparably low rates of hypersensitivity reactions, and a significantly lower incidence of composite cardiovascular AEs.
引用
- Bhandari S, Kalra PA, Berkowitz M, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021. PMID: 32049331. doi:10.1093/ndt/gfaa011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。